The purpose of this shared resource is to provide human tissues, biological fluids, and expert pathologic interpretation for investigators in all of the projects under the direction of expert pathologists. The Histopathology and Tissue/Biologic Fluids Resource has been in existence since 1986 and expanded under the support of the GI SPORE. As of this year, the Resource includes 1698 banked colorectal carcinoma resection specimens, 354 colorectal adenoma samples, 325 hepatic metastases of colorectal carcinoma, 1013 pancreatic carcinoma specimens, 588 xenografts of colorectal carcinoma, 101 pancreatic carcinoma xenografts, 5298 blood specimens from individuals at risk for colorectal carcinoma, and 867 blood specimens from patients with pancreatic carcinoma. Formalin-fixed paraffin-embedded tissues, frozen materials and clinical and outcome data are available for the vast majority of resection specimens. Most recently, this resource has expanded its collections to include high quality snap frozen and formalin fixed samples of end stage pancreatic or colorectal cancer from 120 rapid autopsy participants. 133 tissue microarrays of colorectal and pancreatic neoplasms and diseases have been created. Eight fully characterized pancreatic carcinoma cell lines have been prepared from human tumors and shared with the ATCC. The biospecimens are harvested and banked in accordance with the National Cancer Institute's Best Practice Guidelines for Biorepositories. Distribution of these specimens to SPORE investigators has resulted in over 100 publications. This Core procures additional xenografts, fresh frozen colorectal and pancreatic neoplasms and blood and pancreatic juice samples, and provides expert pathologic consultation to investigators. Specimens are collected under the supervision of pathologists with expertise in colorectal and pancreatic neoplasia in close collaboration with clinical specialists in these areas and in similarly close collaboration with basic research investigators to maximize translational impact of the projects. Clinical and family histories are entered into a password protected web-based tracking system for our pancreatic cases. This Web-based interface follows the recommendations of the National Research Council, and includes user authentication, encryption, audit trails, and disaster recovery. A mechanism is in place for prioritization of distribution of requested resources to investigators within and external to the Johns Hopkins GI Cancer SPORE. Biosamples have been shared with investigators at over 50 other institutions. Collaboration with investigators at other centers fosters the accrual of rare tumor types.

Public Health Relevance

Neoplasms of the pancreas and colon are among the most common causes of cancer related death in the United States. This core resource will thus support the projects of this application related to the diagnosis and treatment of pancreatic and/or colorectal neoplasia with high quality tissues and biosamples.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA062924-20
Application #
8559520
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
20
Fiscal Year
2013
Total Cost
$116,854
Indirect Cost
$44,551
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Cohen, Joshua D; Li, Lu; Wang, Yuxuan et al. (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359:926-930
Shumar, Stephanie A; Kerr, Evan W; Geldenhuys, Werner J et al. (2018) Nudt19 is a renal CoA diphosphohydrolase with biochemical and regulatory properties that are distinct from the hepatic Nudt7 isoform. J Biol Chem 293:4134-4148
Li, Yuguo; Qiao, Yuan; Chen, Hanwei et al. (2018) Characterization of tumor vascular permeability using natural dextrans and CEST MRI. Magn Reson Med 79:1001-1009
Saung, May Tun; Muth, Stephen; Ding, Ding et al. (2018) Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer 6:118
Canto, Marcia Irene; Almario, Jose Alejandro; Schulick, Richard D et al. (2018) Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology 155:740-751.e2
Makohon-Moore, Alvin P; Matsukuma, Karen; Zhang, Ming et al. (2018) Precancerous neoplastic cells can move through the pancreatic ductal system. Nature 561:201-205
Chu, Nam; Salguero, Antonieta L; Liu, Albert Z et al. (2018) Akt Kinase Activation Mechanisms Revealed Using Protein Semisynthesis. Cell 174:897-907.e14
Felsenstein, Matthäus; Noë, Michaël; Masica, David L et al. (2018) IPMNs with co-occurring invasive cancers: neighbours but not always relatives. Gut 67:1652-1662
Grant, Robert C; Denroche, Robert E; Borgida, Ayelet et al. (2018) Exome-Wide Association Study of Pancreatic Cancer Risk. Gastroenterology 154:719-722.e3
Tie, Jeanne; Cohen, Joshua D; Wang, Yuxuan et al. (2018) Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut :

Showing the most recent 10 out of 883 publications